Biopharmaceutical company studies a Safety and Tolerability of Abelacimab vs. Rivaroxaban in Patients With Atrial Fibrillation

Photo by Christina Victoria Craft

Anthos Therapeutics, Inc in collaboration with the TIMI Study Group and Covance is starting a new clinical trial of Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation.

The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

Among the exclusion criteria are:

  • History of hypersensitivity to any of the study drugs (including rivaroxaban) or its excipients, to drugs of similar chemical classes, or any contraindication listed in the label for rivaroxaban.
  • Patients with an intracranial or intraocular bleed within the 3 months prior to screening.
  • Clinically significant mitral stenosis (valve area <1.5 cm2).
  • Mechanical heart valve.
  • Known presence of an atrial myxoma or left ventricular thrombus.
  • History of left atrial appendage closure or removal.
  • Active endocarditis.

The clinical trial started in February 2, 2021 and will continue throughout May 2023.

The contacts and locations are the Anthos Investigative Site, Odessa, Texas, United States.

Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm (arrhythmia) characterized by the rapid and irregular beating of the atrial chambers of the heart. It often begins as short periods of abnormal beating, which become longer or continuous over time. It may also start as other forms of arrhythmia such as atrial flutter that then transform into AF. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain. The disease is associated with an increased risk of heart failure, dementia, and stroke. It is a type of supraventricular tachycardia.

For more details:

Clinical Research News